부산대학교 도서관

This letter, published in the Journal of Neurology, presents a case report of a patient with generalized myasthenia gravis (MG) who experienced a severe myasthenic crisis. The patient was resistant to multiple standard therapies, including intravenous immunoglobulins (IVIg), immunoadsorption, and rituximab. However, the initiation of ravulizumab, a complement inhibitor, led to significant improvement in neuromuscular functions within a week. The patient's condition remained stable over a 19-week follow-up period, with further enhancements in quality of life observed. The authors suggest that complement inhibitors like ravulizumab may be a promising additional treatment strategy for refractory myasthenic crises, but further studies are needed to evaluate their effectiveness. [Extracted from the article]